| Active substance | vorasidenib |
| Holder | Servier Belux |
| Status | Running |
| Indication | the treatment of predominantly non-enhancing grade 2 astrocytoma or oligodendroglioma (as per World Health Organization (WHO) 2021 criteria) with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12 years and older and weighing >40kg who only had surgical intervention including biopsy, subtotal resection or gross total resection and are not in immediate need of radiotherapy or chemotherapy |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 31/01/2025 |